Ondansetron Stada (Ondansetron)

Ondansetron Stada is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients.
• Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy.
• Post‑operative nausea and vomiting: decreases incidence of nausea after surgical procedures.
• Pregnancy‑related nausea (hyperemesis gravidarum): provides relief when other treatments are ineffective.
• Anticipatory nausea: lessens nausea that occurs before chemotherapy in patients with a history of severe CINV.

• Ondansetron selectively blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents serotonin‑mediated signaling that initiates the vomiting reflex, thereby reducing nausea and vomiting associated with chemotherapy, radiation, and surgery.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel movement difficulty.
• Diarrhoea: loose stools in some patients.
• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with IV use.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes.
• Vision changes: blurred vision or visual disturbances.

When using Ondansetron Stada, consider the following precautions to ensure safe and effective therapy.

• Cardiac monitoring: assess baseline ECG in patients with known heart disease.
• Drug interactions: review concomitant medications that may affect QT interval.
• Renal impairment: adjust dosing in severe renal dysfunction.
• Hepatic impairment: use caution in patients with liver disease.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Apomorphine: may cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic drugs (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome.
• Antifungal azoles (ketoconazole, fluconazole): may increase plasma levels of ondansetron.
• Macrolide antibiotics (erythromycin, clarithromycin): can affect cardiac conduction.
• Chemotherapy agents (cisplatin, cyclophosphamide): additive QT‑prolonging effect.
• Oral contraceptives: may reduce effectiveness of hormonal contraception.